Environmental and NSAID-enteropathy: dysbiosis as a common factor

Curr Gastroenterol Rep. 2014 Mar;16(3):377. doi: 10.1007/s11894-014-0377-1.

Abstract

At first sight, environmental enteropathy and NSAID enteropathy may appear to have little in common. One occurs almost exclusively in poor countries and the other primarily in rich countries. One is the consequence of unhygienic living conditions, while the other is a consequence of use of a drug for relief of pain and inflammation. However, there may be a common pathogenic link between these two conditions, namely a significant alteration in the microbiome (dysbiosis), and this raises the possibility of common approaches to treatment. Correction of the dysbiosis that is central to the intestinal tissue injury and dysfunction observed in environmental and nonsteroidal anti-inflammatory drug (NSAID)-induced enteropathies is a logical approach to bringing about restoration of intestinal function. For both conditions, removal of the trigger for dysbiosis is the simplest approach, but is not always feasible. Correcting the underlying dysbiosis through the use of probiotics or prebiotics may be a viable option.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Dysbiosis / complications*
  • Dysbiosis / therapy
  • Environmental Exposure / adverse effects*
  • Humans
  • Intestinal Diseases / etiology*
  • Intestinal Diseases / microbiology
  • Intestinal Diseases / therapy
  • Probiotics / therapeutic use

Substances

  • Anti-Inflammatory Agents, Non-Steroidal